Evaxion A (EVAX) EBITDA Margin (2024 - 2025)
Evaxion A (EVAX) posted EBITDA Margin of 39.94% for Q3 2025, down 97.79% quarter-over-quarter from 1808.11% in Q2 2025, and up 9731.0% year-on-year from 0.41% in Q3 2024.
Evaxion A (EVAX) EBITDA Margin (2024 - 2025) Analysis & Trends
Evaxion A (EVAX) has reported EBITDA Margin for 2 consecutive years, with 39.94% the latest figure, recorded in Q3 2025.
- EBITDA Margin for Q3 2025 came in at 39.94%, up 9731.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 125.36% (up 16602.0% YoY), and the FY2025 annual result was 122.66%, up 31789.0% from the prior year.
- EBITDA Margin was 39.94% for Q3 2025 at Evaxion A, down from 1808.11% in the prior quarter.
- Over five years, EBITDA Margin peaked at 1808.11% in Q2 2025 and troughed at 8619.61% in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Genmab A | 276,399.99 Bn | 276,398.47 Bn | 831.00 Mn | -11.83% |
| 2 | Akari Therapeutics | 1,217.26 Bn | 1,217.26 Bn | - | - |
| 3 | BeOne Medicines | 419.38 Bn | 414.59 Bn | 1.35 Bn | 16.51% |
| 4 | Vertex Pharmaceuticals | 126.54 Bn | 119.30 Bn | 2.59 Bn | 38.10% |
| 5 | Pharming | 110.17 Bn | 110.12 Bn | 65.80 Mn | -6.78% |
| 6 | Regeneron Pharmaceuticals | 64.97 Bn | 56.22 Bn | 3.31 Bn | 18.35% |
| 7 | Argenx Se | 56.44 Bn | 56.44 Bn | 1.18 Bn | 30.35% |
| 8 | Alnylam Pharmaceuticals | 40.09 Bn | 37.08 Bn | 959.66 Mn | 17.24% |
| 9 | Revolution Medicines | 37.15 Bn | 37.15 Bn | - | - |
| 10 | Evaxion A | 1.33 Bn | 1.33 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 40.34% |
| Jun 30, 2025 | 1,808.11% |
| Dec 31, 2024 | -3,298.36% |
| Sep 30, 2024 | -57.37% |
| Jun 30, 2024 | 18.18% |
| Mar 31, 2024 | -8,619.61% |